<DOC>
	<DOCNO>NCT01482949</DOCNO>
	<brief_summary>The purpose study evaluate clinical response AGS-003 alone combination sunitinib therapy .</brief_summary>
	<brief_title>A Rollover Protocol Subjects Previously Treated With AGS-003</brief_title>
	<detailed_description>AGS-003-005 rollover , open label , Phase II clinical study test biologic activity safety AGS-003 subject experience either partial response prolong stable disease continue benefit ongoing treatment AGS-003 protocols AGS-003-004 AGS-003-006 . Rollover subject AGS-003-004 continue AGS-003 monotherapy booster dose disease progression discontinuation criterion reach . Subjects progress AGS-003 monotherapy ( AGS-003-004 protocol ) may start sunitinib treatment re-initiate AGS-003 therapy begin induction phase dose schedule . Rollover subject AGS-003-006 continue sunitinib dose combination booster dose AGS-003 disease progression discontinuation criterion reach . If subject disease progression due new tumor lesion , upon consultation investigator , Argos representative Argos medical monitor , subject may consider re-manufacture study product ( new metastatic lesion ) dose new product combination sunitinib begin induction phase dose schedule . For subject initiate treatment induction phase describe , restaging image occurs screen ( baseline ) , prior fifth dose induction phase ( applicable ) every 12 week booster phase ( start sunitinib holiday , 2 week prior next AGS-003 dose ) . For subject combination therapy , dose sunitinib stop due sunitinib-related issue , treatment AGS-003 may continue . Close-out visit occur upon disease progression ( circumstance discuss eligible re-induction ) upon decision terminate study sponsor . Quarterly follow-up survival subject occur telephone interview 1 year follow last AGS-003 administration study termination .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Age ≥ 18 year Subjects receive ongoing treatment AGS003 protocol AGS 003004 AGS003006 . Measurable disease monitor per RECIST throughout course study participation . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Adequate hematologic function , define follow criterion : 1 . White blood cell ( WBC ) ≥ 4000/µL ( ≥ 4.0 x 103/µL ) 2 . Absolute neutrophil count ( ANC ) ≥ 1500/µL ( ≥ 1.5 x 103/µL ) 3 . Platelets ≥ 100,000/µL ( ≥ 100 x 103/µL ) 4 . Hemoglobin ( Hgb ) ≥ 9.0 g/dL Adequate renal hepatic function , define follow criterion : 1 . Serum creatinine ≤ 1.5 x upper limit normal ( ULN ) , serum creatinine &gt; 1.5 x ULN , estimate glomerular filtration rate ( eGFR ) ≥ 30 mL/min 2 . Total serum bilirubin ≤ 1.5 x ULN 3 . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 x ULN , AST ALT ≤ 5 x ULN liver function abnormality due underlying malignancy Adequate coagulation function define follow criterion : 1 . Prothrombin time ( PT ) ≤ 1.5 x ULN 2 . Activated partial thromboplastin time ( PTT ) &lt; 1.5 x ULN 3 . Corrected calcium ≤ 11.5 mg/dL Negative serum pregnancy test female subject reproductive potential , agreement male female subject reproductive potential use reliable form contraception study 12 week last dose study drug Able abstain take prohibit drug , either prescription non prescription , treatment phase study Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure Signed date informed consent document indicate subject ( legally acceptable representative ) inform pertinent aspect trial prior enrollment No brain metastasis detect magnetic resonance imaging ( MRI ) . Any serious medical condition consider investigator constitute unwarranted high risk investigational treatment History know brain metastasis , spinal cord compression , carcinomatous meningitis , evidence brain leptomeningeal disease screen compute tomography ( CT ) scan MRI Pregnancy breastfeed Active autoimmune disease condition require chronic immunosuppressive therapy NOTE : Abnormal laboratory value autoimmunity marker absence signs/symptoms autoimmune disease exclusionary .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>RCC</keyword>
	<keyword>Kidney Cancer</keyword>
	<keyword>Renal Cancer</keyword>
	<keyword>Arcelis</keyword>
</DOC>